Neonatal severe hyperparathyroidism associated with a novel de novo heterozygous R551K inactivating mutation and a heterozygous A986S polymorphism of the calcium-sensing receptor gene

Judit Toke; Gábor Czirják; Attila Patócs; Balázs Enyedi; Péter Gergics; Violetta Csákváry; Péter Enyedi; Miklós Tóth

P497

Prev Next

Section Contents Cite

Endocrine Abstracts (2007) 14 P497

ECE2007 Poster Presentations (1) (659 abstracts)

Neonatal severe hyperparathyroidism associated with a novel de novo heterozygous R551K inactivating mutation and a heterozygous A986S polymorphism of the calcium-sensing receptor gene

Judit Toke ¹ , Gábor Czirják ² , Attila Patócs ¹ , Balázs Enyedi ² , Péter Gergics ¹ , Violetta Csákváry ³ , Péter Enyedi ² & Miklós Tóth ¹

Err

Author affiliations

¹Semmelweis University, 2nd Department of Medicine, Budapest, Hungary; ²Semmelweis University, Department of Physiology, Budapest, Hungary; ³Markusovszky Teaching Hospital of Vas County, Department of Pediatrics, Szombathely, Hungary.

Objectives: Neonatal severe hyperparathyroidism (NSHPT) is induced by inactivating mutations of human calcium-sensing receptor (CaSR). We report the case of a now 11 year-old boy with NSHPT. We characterize a novel inactivating mutation with the results of some functional analyses.

Case: In the neonatal age the patient presented the clinical syndrome of NSHPT. At the age of 6 years, persisting hypercalcemia without clinical symptoms was documented, and the patient remained completely symptom-free without parathyroid surgery until his present age of 11 years.

Methods: The entire coding region of the CaSR gene of the patient, and exons 6 and 7 from his family members were sequenced. Functional investigation was performed in HEK-293 cells, transiently transfected with wild type and mutant CaSR plasmid constructs.

Results: Sequence analysis revealed a novel de novo heterozygous mutation at codon 551 (AGG→AAG) predicting a change of arginine to lysine (R551K) and a known heterozygous polymorphism (A986S) on the same allele, which was inherited from the father. We demonstrated that the novel R551K mutation significantly reduced the calcium sensitivity of CaSR (EC50: from 3.38±0.62 to 6.10±0.83 mmol/l) which was not alleviated by the simultaneous presence of A986S polymorphism.

Conclusion: We present the fourth NSHPT case induced by a novel de novo heterozygous inactivating mutation (R551K) of the CaSR gene. The disease gradually reverted to a symptomless, benign condition resembling familial hypocalciuric hypercalcemia without any surgical intervention.